Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer - O'Malley, D M; Matulonis, U A; Birrer, M J (Gynecol Oncol, 2020)